Evolus Reports 7% Q1 Revenue Growth, Reaffirms 2026 Guidance
EOLS sits 50% above its 52-week low of $3.86 on elevated volume (2.0× avg).
Summary
Evolus reported a 7% year-over-year increase in Q1 revenue to $72.75 million, driven by strong sales of Jeuveau and HA gels. Notably, the company achieved its second consecutive quarter of positive adjusted EBITDA, signaling improved operational leverage. Despite a net loss of $10.67 million, Evolus reaffirmed its full-year 2026 guidance for double-digit revenue growth and positive adjusted EBITDA margin. This update provides a positive operational trend following the previous 10-K which noted wider net losses and higher cash burn. The reaffirmed guidance offers stability and confidence in the company's outlook, suggesting continued execution on its product strategy. Investors will now focus on sustained operational improvements and progress towards overall profitability.
At the time of this announcement, EOLS was trading at $5.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $363M. The 52-week trading range was $3.86 to $12.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.